Article Sidebar

PDF
Date Published: 28/02/2026
Abstract Views: 38
Views PDF: 12
DOI: 10.56535/jmpm.v51i2.1763
Issue
Vol. 51 No. 2 (2026): JOURNAL OF MILITARY PHARMACO-MEDICINE No.2 - 2026
Section
Articles
How to Cite
Tran, D. L., Nguyen, D. L., & Nguyen, V. B. (2026). SIX-MONTH OUTCOMES OF COMBINED GAMMA KNIFE RADIOSURGERY AND TKIs FOR BRAIN METASTASES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER. Journal of Military Pharmaco-medicine, 51(2), 116-123. https://doi.org/10.56535/jmpm.v51i2.1763

SIX-MONTH OUTCOMES OF COMBINED GAMMA KNIFE RADIOSURGERY AND TKIs FOR BRAIN METASTASES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Duc Linh Tran1,2, , Duc Lien Nguyen3,4, Van Ba Nguyen1,2
1 Học viện Quân y
2 Bệnh viện Quân y 175
3 Bệnh viện K
4 Đại học Y Hà Nội

Main Article Content

Abstract

Objectives: To evaluate the 6-month outcomes of a combined regimen of Gamma Knife radiosurgery and tyrosine kinase inhibitors (TKIs) in patients with brain metastases from non-small cell lung cancer (NSCLC). Methods: A longitudinal observational study was conducted on 74 patients with NSCLC-related brain metastases treated  at Viet Nam National Cancer Hospital from February 2021 to December 2024. Results: At a six-month follow-up, 56.4% of patients with an initial Karnofsky Performance Status (KPS) of 70 - 80 improved to 90 - 100 (p < 0.01). The intracranial response rate was 79.7%, with 32.4% of patients achieving a complete response. Total tumor volume and the number of radiosurgery fractions were significantly correlated with the treatment response (p < 0.01). Conclusion: The combination of Gamma Knife radiosurgery and TKIs significantly improved both the overall clinical status and provided intracranial disease control for NSCLC patients and brain metastases after 6 months of treatment.

Keywords

Non-small cell lung cancer, Brain metastases, Gamma Knife radiosurgery, TKIs

Article Details

References

1. Freddie Bray, Mathieu Laversanne, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024; 71(3):209-249.
2. Chiou GY, Chiang CL, Yang HC, et al. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. Journal of Neurosurgery. 2021; 1 (aop):1-8.
3. Nguyễn Văn Kiên, Phạm Cẩm Phương và CS. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ di căn não có đột biến EGFR bằng thuốc ức chế Tyrosine Kinase kết hợp xạ phẫu dao Gamma quay tại Bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2021; 506(2).
4. Phan Thanh Dương. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ di căn não bằng xạ phẫu Gamma Knife. Luận văn Chuyên khoa cấp II. Đại học Y Hà Nội. 2020.
5. Li B, Yu J, Suntharalingam M, et al. Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer. 2000; 90(1):37-45.
6. Lee CC, Hsu SPC, Lin CJ, et al. Epidermal growth factor receptor mutations: Association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases. J Neurosurg. 2020; 133(2):313-320.
7. Byeon S, Ham JS, Sun JM, et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol. 2016; 33(8):97.
8. Bhatnagar AK, Flickinger JC, Kondziolka D, et al. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys. 2006; 64(3):898-903.
9. Serizawa T, Yamamoto M, Higuchi Y, et al. Local tumor progression treated with Gamma Knife radiosurgery: Differences between patients with 2 - 4 versus 5 - 10 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901). J Neurosurg. 2020; 132(5):1480-1489.